You are here

Regeneron

Regeneron wins bid to buy 23andMe out of bankruptcy

BioPharma Dive

Mon, 05/19/25 - 11:29 am

genetic testing

Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit

Fierce Pharma

Fri, 05/16/25 - 11:40 am

Regeneron's Eylea franchise suffers double whammy with sales decline and surprise FDA rejection

Fierce Pharma

Wed, 04/30/25 - 11:13 am

Regeneron signs $3 billion deal with contract drugmaker to boost US manufacturing

MSN/Reuters

Tue, 04/22/25 - 11:40 am

Fujifilm Diosynth Biotechnologies

drug manufacturing

Sanofi, Regeneron win FDA nod for Dupixent in chronic hives

BioPharma Dive

Mon, 04/21/25 - 11:13 am

FDA rejection of extended dosing interval is another piece of bad news for Regeneron’s Eylea HD

Fierce Pharma

Mon, 04/21/25 - 10:22 am

Regeneron clears FDA enrollment hurdle for odronextamab review

First Word Pharma

Wed, 02/26/25 - 10:17 pm

follicular lymphoma

Regeneron's gene therapy study shows improved hearing in children with congenital deafness

Contemporary Pediatrics

Mon, 02/24/25 - 05:05 pm

genetic hearing loss

genetic deafness

Regeneron tangles with Sanofi over commercial transparency in long-running Dupixent collaboration

Fierce Pharma

Thu, 02/6/25 - 10:50 pm

Regeneron Beats Quarterly Estimates on Eczema Drug Demand; Launches Dividend Program

US News and World Report

Tue, 02/4/25 - 09:25 am

Regeneron patents block biosimilar entry for Eylea

Patently-O

Thu, 01/30/25 - 11:26 pm

Regeneron Acquisition of Oxular Wipes Out Oxular Workforce

BioSpace

Sun, 01/5/25 - 09:38 pm

Regeneron acquires UK biotech, adding Oxular's eye disease delivery tech to portfolio

Fierce Biotech

Fri, 01/3/25 - 10:51 am

retinal disease

Regeneron anticoagulant bests enoxaparin, matches Eliquis in phase 2 trial

Fierce Biotech

Thu, 12/19/24 - 11:31 am

clinical trials

Regeneron, Bayer Build Retinal Vein Occlusion Case for Eylea as Biosimilar Pressure Mounts

BioSpace

Wed, 12/18/24 - 11:12 am

retinal vein occlusion

Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma

Pharma Voice

Thu, 12/12/24 - 11:33 am

FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease

Benzinga

Fri, 11/15/24 - 11:15 am

chronic spontaneous urticaria

Regeneron Reports Mixed Q3 Sales as Eylea Franchise Remains Under Pressure

BioSpace

Fri, 11/1/24 - 10:54 am

Regeneron loses bid to block Amgen's Eylea biosimilar launch in US

Reuters

Tue, 10/22/24 - 11:30 pm

Regeneron takes the long-haul approach to oncology, stumbles and all

Pharma Voice

Thu, 10/10/24 - 09:52 am

Pages